Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- α protein. Trichosanatine can alleviate oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1/p38 MAPK pathway.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | $ 950.00 | |
1 mL * 10 mM (in DMSO) | Inquiry | $ 970.00 |
Description | Trichosanatine and squamosamide, as potential candidates as lead compounds for further study in drug development process with the PP2A- α protein. Trichosanatine can alleviate oxidized low-density lipoprotein induced endothelial cells injury via inhibiting the LOX-1/p38 MAPK pathway. |
Source |
Molecular Weight | 444.52 |
Formula | C27H28N2O4 |
CAS No. | 169626-16-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Trichosanatine 169626-16-8 Immunology/Inflammation MAPK Metabolism Proteases/Proteasome p38 MAPK LDL MMP ROS Lipoxygenase inhibitor inhibit